Beta-catenin and b-cell lymphoma 9 (bcl9) inhibitors

A compound having Formula I.

• or a pharmaceutically acceptable salt thereof, wherein
• L1 is O, S, or NH;
• each of R1a and R1b is independently hydrogen, halogen, C1-C3 alkyl, C1-C3 monohaloalkyl, or C1-C3 polyhaloalkyl;
• each of R2a, R2b, and R2c is independently hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl, or C1-C3 polyhaloalkyl;
• R3 is Cy3 or Ar1;
• wherein Cy3 is a C3-C8 cycloalkyl or a C2-C7 heterocycloalkyl and Ar is selected from aryl and heteroaryl, wherein Cy3 and Ar1, when present, are substituted with 0, 1, 2, or 3 groups independently selected from halogen, —CN, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, cyclopropyl, and —CO2H;
• R4 is hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl, or C1-C3 polyhaloalkyl;
• wherein each occurrence of R5 is independently selected from hydrogen, C1-C3 alkyl;
• R6 is C1-C6 aminoalkyl, C1-C6 hydroxyalkyl, or Cy1;
• and wherein Cy1 is an amino C3-C8 cycloalkyl, a hydroxy C3-C8 cycloalkyl, or a C2-C7 heterocycloalkyl comprising at least one oxygen or nitrogen atom;
• and wherein Cy1 is substituted with 0, 1, 2, or 3 groups independently selected from halogen, C1-C4 alkyl, C1-C4 monohaloalkyl, and C1-C4 polyhaloalkyl;
• R7 is C3-C6 heterocycloalkyl-(C═O)—NR12—, wherein said C3-C6 heterocycloalkyl comprises at least one nitrogen atom;
• and
• R12 is selected from hydrogen or C1-C3 alkyl.